Background/aimPeripheral nerve injuries (PNI) are debilitating disorders affecting predominantly the younger generation, often leading to significant disabilities. Current treatment strategies are inadequate in addressing the complex nature of these injuries. Peripheral nerve healing and functional recovery are crucial components of both pathophysiology and therapeutic approach. High fructose corn syrup (HFCS) is a frequently used sweetener in several beverages and foods. And it is associated with several metabolic disturbances including insulin resistance and may impair nerve healing. This study investigates the therapeutic role of ivermectin on nerve regeneration following sciatic nerve injury and evaluates motor and sensorial functions together with histopathological evaluation. Additionally, we aimed to compare nerve healing between animals that consume high-fructose and those that do not.Materials and methodsForty-eight male Swiss albino mice were randomly divided into six groups, first-half consuming HFCS-42 (11% v/v) and the second-half regular tap-water for 8 weeks. On 28th day, sciatic nerve injury (SNI) was performed on all groups. Ivermectin (1 mg/kg) or gabapentin (30 mg/kg) treatments were administered to selected groups. Body weight, blood glucose, motor function (Rotarod, open field test) and thermal-mechanical sensorial functions were assessed weekly. Finally, insulin levels were measured, and histopathological samples were taken.Results8 weeks of HFCS impaired mechanical-thermal sensorial functions with histopathologically poor nerve repair. Ivermectin resulted in improved sensorial and faster motor function recovery in HFCS groups. Elevated plasma insulin levels-HOMA-IR values were diminished by ivermectin in HFCS groups. In ivermectin non-HFCS group, histopathology revealed accelerated healing and higher scores in total. Ivermectin also ameliorated mechanical sensation loss after SNI alongside with cold sensation.ConclusionIvermectin accelerated sensorial and motor nerve recovery resulting in faster nerve healing alongside improved insulin-resistance, suggesting it might serve as a potential foundation for developing a new treatment for nerve regeneration after injury.
Objective: Follicular-fluid biomarkers may characterize the peri-oocyte microenvironment, but their incremental value beyond established ovarian-reserve tests is uncertain. Methods: This prospective observational study included 42 women aged 18–40 years undergoing in vitro fertilization at Ankara Etlik City Hospital, including 21 with diminished ovarian reserve and 21 with unexplained infertility. Follicular-fluid anti-Müllerian hormone was measured by electrochemiluminescence immunoassay and leptin by enzyme-linked immunosorbent assay. Results: Pregnancy analyses used complete-case data from 22 of 25 women who underwent embryo transfer. Follicular-fluid anti-Müllerian hormone was lower in the diminished ovarian reserve group [1.13 (0.94–1.45) versus 3.40 (2.69–5.93) nanograms per milliliter; P<0.001], whereas leptin was similar (1243.73±340.50 versus 1265.78±233.35 picograms per milliliter; P=0.808). Women with diminished ovarian reserve had fewer retrieved, mature, and fertilized oocytes. Fourteen clinical pregnancies occurred among the 22 transfers with complete follow-up. Serum and follicular-fluid anti-Müllerian hormone and antral follicle count were higher among women with clinical pregnancy, but exploratory penalized regression did not identify anti-Müllerian hormone as an independent predictor. Leptin was not associated with infertility group or clinical pregnancy. Conclusion: Follicular-fluid anti-Müllerian hormone appears to reflect ovarian-reserve phenotype and granulosa-cell activity rather than provide proven incremental clinical value over serum anti-Müllerian hormone and antral follicle count. Larger follicle-matched studies with live-birth endpoints are required before either marker is used in routine clinical decision-making.